… Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by …
Coronavirus disease 2019 (COVID-19) pandemic is an ongoing threat to global health. COVID…

… treating patients with coronavirus disease 2019 (COVID-19). The aim of this study was to
assess the clinical efficacy of HIVC on hyperinflammation in patients with severe COVID-19. …

… of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from
China showed that about 20% of patients developed severe disease, … of critical COVID-19 …

… P2X7R antagonist lidocaine can abrogate hyperinflammation and restore the normal immune
… ) local hyperinflammation. We illustrate this with six critically ill COVID-19 patients treated …

… 41,570,883 confirmed cases and 1,134,940 coronavirus disease 2019 (COVID-19)-related
deaths worldwide (1). In critically ill adult patients, hyperinflammation is considered to play a …

… Dexamethasone was also more effective in patients randomized to receive treatment for >7
versus ≤7 days after the onset of COVID-19 symptoms (P < 0.001). Dexamethasone was the …

… In some patients, the resulting hyperinflammation resembles … of the immunopathogenesis
of coronavirus disease 2019 is … a treatment option for adults with severe coronavirus disease …

… modality for treating dysregulated inflammatory responses in COVID-19, … diseases have
indicated the possibility of applying exosomes in the treatment of hyper-inflammation in COVID-…

… with coronavirus disease 2019 (COVID-19) has been described [1]; we write to share our
experience treating a 17… to the scientific community as a treatment option in COVID-19 infection. …

… insights into the differential COVID-19 pathology in patients treated with ACEI/ARB compared
to patients without cardiovascular diseases or with a different anti-hypertensive treatment. …